IRIDEX (IRIX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $11.6 million, down 10% year-over-year, with a net loss of $1.9 million ($0.12 per share), driven by softness in the retina business and regulatory shipment delays.

• Cost reduction initiatives and a $3.4 million convertible note improved liquidity and are expected to drive EBITDA breakeven in Q4 2024.

• Strategic review process is ongoing, with active discussions and potential transactions anticipated before year-end.

• Leadership transition with Patrick Mercer appointed CEO to accelerate strategic review and cost-cutting.

• Declines were driven by softer demand in Retina and Glaucoma product lines and lower royalties due to patent expirations.

Financial highlights

• Q3 2024 revenue was $11.6 million, down 10% year-over-year; gross profit was $4.3 million with a 37.3% margin, down from 43.7% last year.

• Operating expenses for Q3 2024 were $6.2 million, down 15.3% year-over-year, reflecting cost reductions.

• Net loss was $1.9 million ($0.12 per share), slightly higher than last year's $1.8 million ($0.11 per share).

• Cash and cash equivalents at quarter-end were $3.9 million, bolstered by $3.4 million in convertible note proceeds.

• Convertible note payable outstanding was $2.7 million, with $1.3 million short-term and $1.4 million long-term.

Outlook and guidance

• Q4 is expected to be EBITDA positive due to cost reductions and improved profitability.

• Regulatory shipment delays in the retina segment are expected to resolve in Q4, supporting revenue recovery.

• New Medicare LCD reimbursement policy for glaucoma, effective November 17, 2024, is anticipated to drive increased adoption of laser consoles and probes.

• Management expects cost savings and recent financing to support liquidity through January 2026.

• Persistent macroeconomic concerns and capital spending delays in healthcare may continue to impact demand.